This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Selander, K. S. Articles by Harris, K. W. Search for Related Content PubMed PubMed Citation Articles by Selander, K. S. Articles by Harris, K. W.

Inhibition of gp130 Signaling in Breast Cancer Blocks Constitutive Activation of Stat3 and Inhibits in Vivo Malignancy

¹ Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama; ² Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; ³ Institut für Biochemie, Universitätsklinikum Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany

The cytokine receptor gp130 is the common signaling subunit of receptors used by the interleukin (IL)-6 cytokine family. gp130 is widely expressed in breast cancer cell lines and primary tumors. The role of gp130 in breast cancer in vivo is unknown. To study the effect of gp130 inhibition in breast cancer, endogenous gp130 signaling in breast cancer cell lines was blocked with a dominant-negative gp130 protein (DN gp130). DN gp130 inhibited constitutive Stat3 activation in breast cancer cells. Both gp130 and epidermal growth factor receptor (EGFR) have been implicated in constitutive Stat3 activation in breast cancer. There are known physical and functional interactions between gp130 and EGFR. Consistent with this, we show that DN gp130 inhibits signaling downstream of the EGFR in breast cancer cells. The effect of DN gp130 on breast cancer in vivo was assessed with an orthotopic nude mouse model. DN gp130 MDA-231 cells had markedly decreased engraftment, size, and metastasis compared with control cells. These results are particularly striking considering that DN gp130-expressing breast cancer cells grow faster in vitro. We hypothesized that DN gp130 expression results in inhibition of invasion and metastasis in vivo. Marked angiogenesis was present in tumors from control animals and was absent in tumors from DN gp130 animals. We additionally show that tissue inhibitor of metalloproteinase-3, an inhibitor of tumor invasion and angiogenesis, is up-regulated in both MDA-231 DN gp130 cells and tumors. These results, in light of the availability of several potential pharmacological inhibitors of gp130, suggest novel approaches to breast cancer therapy.

This article has been cited by other articles:

				A. W. Studebaker, G. Storci, J. L. Werbeck, P. Sansone, A. K. Sasser, S. Tavolari, T. Huang, M. W.Y. Chan, F. C. Marini, T. J. Rosol, et al. Fibroblasts Isolated from Common Sites of Breast Cancer Metastasis Enhance Cancer Cell Growth Rates and Invasiveness in an Interleukin-6-Dependent Manner Cancer Res., November 1, 2008; 68(21): 9087 - 9095. [Abstract] [Full Text] [PDF]

				S. Y. Cheranov, M. Karpurapu, D. Wang, B. Zhang, R. C. Venema, and G. N. Rao An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis Blood, June 15, 2008; 111(12): 5581 - 5591. [Abstract] [Full Text] [PDF]

				A. K. Sasser, N. J. Sullivan, A. W. Studebaker, L. F. Hendey, A. E. Axel, and B. M. Hall Interleukin-6 is a potent growth factor for ER-{alpha}-positive human breast cancer FASEB J, November 1, 2007; 21(13): 3763 - 3770. [Abstract] [Full Text] [PDF]

				K. Srivastava, V. Kundumani-Sridharan, B. Zhang, A. K. Bajpai, and G. N. Rao 15(S)-Hydroxyeicosatetraenoic Acid-Induced Angiogenesis Requires STAT3-Dependent Expression of VEGF Cancer Res., May 1, 2007; 67(9): 4328 - 4336. [Abstract] [Full Text] [PDF]

				D. Wang, Z. Liu, Q. Li, M. Karpurapu, V. Kundumani-Sridharan, H. Cao, N. Dronadula, F. Rizvi, A. K. Bajpai, C. Zhang, et al. An Essential Role for gp130 in Neointima Formation Following Arterial Injury Circ. Res., March 30, 2007; 100(6): 807 - 816. [Abstract] [Full Text] [PDF]

				M. A. Merrell, J. M. Ilvesaro, N. Lehtonen, T. Sorsa, B. Gehrs, E. Rosenthal, D. Chen, B. Shackley, K. W. Harris, and K. S. Selander Toll-Like Receptor 9 Agonists Promote Cellular Invasion by Increasing Matrix Metalloproteinase Activity Mol. Cancer Res., July 1, 2006; 4(7): 437 - 447. [Abstract] [Full Text] [PDF]

				C. Stuhlmann-Laeisz, S. Lang, A. Chalaris, P. Krzysztof, S. Enge, J. Eichler, U. Klingmuller, M. Samuel, M. Ernst, S. Rose-John, et al. Forced Dimerization of gp130 Leads to Constitutive STAT3 Activation, Cytokine-independent Growth, and Blockade of Differentiation of Embryonic Stem Cells Mol. Biol. Cell, July 1, 2006; 17(7): 2986 - 2995. [Abstract] [Full Text] [PDF]

				M. T. Gillespie and T. A. Guise Bone Marrow-Derived Cells - Fertilizer Necessary for the Seed and Soil IBMS BoneKEy, April 1, 2006; 3(4): 16 - 18. [Abstract] [Full Text] [PDF]

				D. A. de Idiaquez, D. E. Branam, L. Lamb, D. Chen, L. Teng, K. S. Selander, and K. W. Harris Inhibition of Cytokine Receptor gp130 Signaling in Breast Cancer Cells Markedly Suppresses Secretion of Tissue Factor-Expressing Tumor Microparticles. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1935 - 1935. [Abstract]